Obinutuzumab in Primary FSGS

Primary Focal Segmental Glomerulosclerosis Clinical Trial

Official title:
A Single-center, Phase 2 Open-label Trial Evaluating the Efficacy and Safety of OBINUTUZUMAB in Treatment of Immunosuppression-dependent or Immunosuppression/Treatment-resistant Primary FSGS, or Contraindication/Patient Refusal to Take High Dose Corticosteroids

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Glomerulosclerosis, Focal Segmental
Primary Focal Segmental Glomerulosclerosis

Clinical Trial Details

NCT number	NCT04983888
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 17, 2021
Completion date	September 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01573533` - A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS	Phase 2
Not yet recruiting	`NCT06466135` - Study of WAL0921 in Patients With Glomerular Kidney Diseases	Phase 2
Completed	`NCT01665391` - A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)	Phase 2
Completed	`NCT03422510` - FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)	Phase 2
Not yet recruiting	`NCT06315504` - Circulating Factors in Nephrotic Syndrome